John Buscombe, Jaroslaw Cwikla, Ann-Marie Quigley, Shaunak Navalkissoor, Dominic Yu
Selective intra-arterial radiotherapy (SIRT) is a technique which has evolved over the past 30 years. In present this is primarily used to treat primary and secondary tumors in the liver. The technique normally depends on the delivery of a therapeutic radiopharmaceutical or radiolabeled particulate via a radiologically placed intra-arterial catheter in the hepatic artery. This is because most of these tumors have a single arterial blood supply but normal hepatocytes are supplied by both the hepatic artery and portal vein...
April 15, 2024: Seminars in Nuclear Medicine
Antti Saraste, Mia Ståhle, Anne Roivainen, Juhani Knuuti
Molecular imaging can detect and quantify pathophysiological processes underlying heart failure, complementing evaluation of cardiac structure and function with other imaging modalities. Targeted tracers have enabled assessment of various cellular and subcellular mechanisms of heart failure aiming for improved phenotyping, risk stratification, and personalized therapy. This review outlines the current status of molecular imaging in heart failure, accompanied with discussion on novel developments. The focus is on radionuclide methods with data from clinical studies...
April 11, 2024: Seminars in Nuclear Medicine
Hojjat Ahmadzadehfar, Robert Seifert, Ali Afshar-Oromieh, Clemens Kratochwil, Kambiz Rahbar
This review paper highlights the transformative role of PSMA-targeted diagnostics and therapy in prostate cancer management, particularly focusing on 177 Lu-PSMA-617, approved by the FDA and EMA for metastatic castration-resistant prostate cancer (mCRPC) patients post-chemotherapy and ARPI treatment. Originating from the VISION trial's success, this paper navigates the current radioligand therapy (RLT) indications, emphasizing practical patient selection, planning, and treatment execution. It critically examines Lu-PSMA's comparative effectiveness against cabazitaxel and Ra-223, addressing decision-making dilemmas for mCRPC treatments...
April 2, 2024: Seminars in Nuclear Medicine
Kornelis S M van der Geest, Olivier Gheysens, Lars C Gormsen, Andor W J M Glaudemans, Charalampos Tsoumpas, Elisabeth Brouwer, Pieter H Nienhuis, Gijs D van Praagh, Riemer H J A Slart
Systemic vasculitides are autoimmune diseases characterized by inflammation of blood vessels. They are categorized based on the size of the preferentially affected blood vessels: large-, medium-, and small-vessel vasculitides. The main forms of large-vessel vasculitis include giant cell arteritis (GCA) and Takayasu arteritis (TAK). Depending on the location of the affected vessels, various imaging modalities can be employed for diagnosis of large vessel vasculitis: ultrasonography (US), magnetic resonance angiography (MRA), computed tomography angiography (CTA), and [18 F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT)...
March 26, 2024: Seminars in Nuclear Medicine
Robert J H Miller, Piotr J Slomka
Myocardial perfusion imaging (MPI), using either single photon emission computed tomography (SPECT) or positron emission tomography (PET), is one of the most commonly ordered cardiac imaging tests, with prominent clinical roles for disease diagnosis and risk prediction. Artificial intelligence (AI) could potentially play a role in many steps along the typical MPI workflow, from image acquisition through to clinical reporting and risk estimation. AI can be utilized to improve image quality, reducing radiation exposure and image acquisition times...
March 22, 2024: Seminars in Nuclear Medicine
Takahiro Higuchi, Sebastian E Serfling, David M Leistner, Thimoteus Speer, Rudolf A Werner
PET probes targeting fibroblasts are frequently used for varying applications in oncology. In recent years, the clinical spectrum has been expanded towards cardiovascular medicine, e.g., after myocardial infarction, in aortic stenosis or as a non-invasive read-out of atherosclerosis. We herein provide a brief overview of the current status of this PET radiotracer in the context of cardiovascular disease, including translational and clinical evidence. In addition, we will also briefly discuss future applications, e...
March 21, 2024: Seminars in Nuclear Medicine
Luca Giovanella, Murat Tuncel, Atena Aghaee, Alfredo Campenni, Petra Petranović Ovčariček, Armando De Virgilio
Molecular imaging is pivotal in evaluating and managing patients with different thyroid cancer histotypes. The existing, pathology-based, risk stratification systems can be usefully refined, by incorporating tumor-specific molecular and molecular imaging biomarkers with theranostic value, allowing patient-specific treatment decisions. Molecular imaging with different radioactive iodine isotopes (ie, I131 , I123 , I124 ) is a central component of differentiated carcinoma (DTC)'s risk stratification while [18 F]F-fluorodeoxyglucose ([18 F]FDG) PET/CT is interrogated about disease aggressiveness and presence of distant metastases...
March 18, 2024: Seminars in Nuclear Medicine
Tugce Telli, Atefeh Hosseini, Stephan Settelmeier, David Kersting, Lukas Kessler, Wolfgang A Weber, Tienush Rassaf, Ken Herrmann, Zohreh Varasteh
Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Myocardial fibrosis plays an important role in adverse outcomes such as heart failure and arrhythmias. As the pathological response and degree of scarring, and therefore clinical presentation varies from patient to patient, early detection of fibrosis is crucial for identifying the appropriate treatment approach and forecasting the progression of a disease along with the likelihood of disease-related mortality. Current imaging modalities provides information about either decreased function or extracellular signs of fibrosis...
March 15, 2024: Seminars in Nuclear Medicine
Giulia Santo, Gianpaolo Di Santo, Irene Virgolini
Peptide receptor radionuclide therapy (PRRT) today is a well-established treatment strategy for patients with neuroendocrine tumors (NET). First performed already more than 30 years ago, PRRT was incorporated only in recent years into the major oncology guidelines, based on its proven efficacy and safety in clinical trials. Following the phase 3 NETTER-1 trial, which led to the final registration of the radiopharmaceutical Luthatera® for G1/G2 NET patients in 2017, the long-term results of the phase 3 NETTER-2 trial may pave the way for a new treatment option also for advanced G2/G3 patients as first-line therapy...
March 15, 2024: Seminars in Nuclear Medicine
Akram Al-Ibraheem, Richard Zimmermann, Ahmed S Abdlkadir, Ken Herrmann
Radiotheranostics, a combination of diagnostic and therapeutic approaches, was first utilized in cancer management using radiopharmaceuticals to both image and selectively treat specific cancer subtypes nearly a century ago. Radiotheranostic strategies rooted in nuclear medicine have revolutionized the treatment landscape for individuals diagnosed with prostate cancer and neuroendocrine tumors in the past 10 years. In specific contexts, these approaches have emerged as the prevailing standard, yielding numerous positive results...
March 13, 2024: Seminars in Nuclear Medicine
Petar Saric, John P Bois, John R Giudicessi, Andrew N Rosenbaum, Joanna E Kusmirek, Grace Lin, Panithaya Chareonthaitawee
Cardiac sarcoidosis (CS), an increasingly recognized disease of unknown etiology, is associated with significant morbidity and mortality. Given the limited diagnostic yield of traditional endomyocardial biopsy (EMB), there is increasing reliance on multimodality cardiovascular imaging in the diagnosis and management of CS, with EMB being largely supplanted by the use of 18 F-fluorodeoxyglucose (FDG-PET) and cardiac magnetic resonance imaging (CMR). This article aims to provide a comprehensive review of imaging modalities currently utilized in the screening, diagnosis, and monitoring of CS, while highlighting the latest developments in each area...
March 12, 2024: Seminars in Nuclear Medicine
Kip E Guja, Kristen N Ganjoo, Andrei Iagaru
Soft tissue sarcomas are a rare and heterogenous group of tumors that account for 2% of all cancer-related deaths. Molecular imaging with FDG PET can offer valuable metabolic information to help inform clinical management of soft tissue sarcomas that is unique and complementary to conventional diagnostic imaging techniques. FDG PET imaging often correlates with tumor grade, can help guide biopsy, and frequently detects additional sites of disease compared to conventional imaging in patients being considered for definitive or salvage therapy...
March 2, 2024: Seminars in Nuclear Medicine
Hedieh Khalatbari, Barry L Shulkin, Marguerite T Parisi
Soft tissue sarcomas account for 6%-8% of pediatric cancers. The rhabdomyosarcoma family is the most frequent soft tissue sarcoma in this age group accounting for 3% of pediatric cancers. Rhabdomyosarcomas are high-grade tumors with a high propensity to metastasize. The risk-adapted, multimodal therapeutic approach for rhabdomyosarcomas incorporates a combination of surgery, radiotherapy, and multi-agent cytotoxic chemotherapy. Soft tissue sarcomas other than rhabdomyosarcoma account for 3%-4% of pediatric cancers...
February 28, 2024: Seminars in Nuclear Medicine
Samia Massalha, John Kennedy, Essam Hussein, Besma Mahida, Zohar Keidar
Multimodality cardiovascular imaging is a cornerstone diagnostic tool in the diagnosis, risk stratification, and management of cardiovascular diseases, whether those involving the coronary tree, myocardial, or pericardial diseases in general and particularly in women. This manuscript aims to shed some light and summarize the very features of cardiovascular disease in women, explore their unique characteristics and discuss the role of cardiovascular imaging in ischemic heart disease and cardiomyopathies. The role of four imaging modalities will be discussed including nuclear medicine, echocardiography, noninvasive coronary angiography, and cardiac magnetic resonance...
February 22, 2024: Seminars in Nuclear Medicine
Gary A Ulaner, Sofia Carrilho Vaz
Positron Emission Tomography (PET) has been growing in usage for patients with breast cancer, due to an increased number of FDA-approved PET radiotracers pertinent to patients with breast cancer as well as increased prospective evidence for the value of these agents. The leading PET radiotracer for patients with breast cancer is 18F-fluorodeoxyglucose (18F-FDG), which measures glucose metabolism. There is prospective evidence for the use of 18F-FDG PET in systemic staging of newly diagnosed locally advanced breast cancer (stages IIB-IIIC), monitoring breast cancer treatment response, and detecting breast cancer recurrence, particularly in no special type (NST) breast cancer...
February 16, 2024: Seminars in Nuclear Medicine
Ozgul Ekmekcioglu, Nathalie L Albert, Kathrin Heinrich, Nelleke Tolboom, Donatienne Van Weehaeghe, Tatiana Traub-Weidinger, Lutfiye Ozlem Atay, Valentina Garibotto, Silvia Morbelli
Sex differences in brain physiology and the mechanisms of drug action have been extensively reported. These biological variances, from structure to hormonal and genetic aspects, can profoundly influence healthy functioning and disease mechanisms and might have implications for treatment and drug development. Molecular neuroimaging techniques may help to disclose sex's impact on brain functioning, as well as the neuropathological changes underpinning several diseases. This narrative review summarizes recent lines of evidence based on PET and SPECT imaging, highlighting sex differences in normal conditions and various neurological disorders...
February 15, 2024: Seminars in Nuclear Medicine
Francesco Giammarile, Peter Knoll, Diana Paez, Enrique Estrada Lobato, Adriana K Calapaquí Terán, Roberto C Delgado Bolton
The field of nuclear medicine has witnessed significant advancements in recent years, particularly in the area of PET imaging. One such development is the use of Fibroblast Activation Protein Inhibitors (FAPI) as a novel radiotracer. FAPI PET imaging has shown promising results in various malignancies, including sarcomas, which are a diverse group of cancers originating from mesenchymal cells. This paper aims to explore the potential of FAPI PET imaging in the diagnosis, staging, and treatment monitoring of sarcomas...
February 15, 2024: Seminars in Nuclear Medicine
M Michael Sathekge, Kirsten Bouchelouche
No abstract text is available yet for this article.
February 14, 2024: Seminars in Nuclear Medicine
Laura Evangelista, Ora Israel
No abstract text is available yet for this article.
February 13, 2024: Seminars in Nuclear Medicine
Christina Baun, Mohammad Naghavid-Behzad, Malene Grubbe Hildebrandt, Oke Gerke, Helge Thisgaard
The gastrin-releasing peptide receptor (GRPR) is known to be overexpressed in breast cancer, making it a promising target for both imaging and therapy within a theranostic framework. Various radioligands targeting GRPR have undergone investigation in preclinical and clinical studies related to breast cancer. This systematic scoping review aimed to assess the current evidence on GRPR-targeted radioligands for diagnostic and therapeutic applications in breast cancer. The methodology followed the PRISMA-ScR protocol...
February 10, 2024: Seminars in Nuclear Medicine
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.